Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bril

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Hepatobiliary Surgery and Nutrition|August 25, 2020
Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward changeFernando Bril
Diabetes, Obesity & Metabolism|March 13, 2026
Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelinesFernando Bril
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide in NASH-related cirrhosis: too late to the party?Fernando Bril
Metabolism and Target Organ Damage|November 3, 2025
Will a "multivitamin" a day keep the "MASLD doctor" away?Fernando Bril
Journal of Hepatology|August 13, 2021
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summerFernando Bril
Ebiomedicine|September 26, 2021
What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)Fernando Bril
Endocrinology and Metabolism Clinics of North America|November 9, 2016
Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes MellitusFernando Bril, Kenneth Cusi
Hepatology (Baltimore, Md.)|March 16, 2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culpritFernando Bril, Kenneth Cusi
Diabetes Care|February 23, 2017
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to ActionFernando Bril, Kenneth Cusi
Metabolism: Clinical and Experimental|November 17, 2024
Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?Fernando Bril, Alicia Elbert
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Hepatobiliary Surgery and Nutrition|August 25, 2020
Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward changeFernando Bril
Diabetes, Obesity & Metabolism|March 13, 2026
Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelinesFernando Bril
The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide in NASH-related cirrhosis: too late to the party?Fernando Bril
Metabolism and Target Organ Damage|November 3, 2025
Will a "multivitamin" a day keep the "MASLD doctor" away?Fernando Bril
Journal of Hepatology|August 13, 2021
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summerFernando Bril
Ebiomedicine|September 26, 2021
What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)Fernando Bril
Endocrinology and Metabolism Clinics of North America|November 9, 2016
Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes MellitusFernando Bril, Kenneth Cusi
Hepatology (Baltimore, Md.)|March 16, 2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culpritFernando Bril, Kenneth Cusi
Diabetes Care|February 23, 2017
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to ActionFernando Bril, Kenneth Cusi
Metabolism: Clinical and Experimental|November 17, 2024
Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?Fernando Bril, Alicia Elbert
Pageof 10